Login
$ABSI
$7.53 +$0.06 (0.74%) After hours

$ABSI SEC Filings

Filed On Filing
13 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 S-3ASR
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month

30 Oct 2026 Form 4: McClain Sean, Director

Gave up 79,860 shares to cover exercise price or tax ($966K)

27 Oct 2026 SCHEDULE 13G/A
14 Oct 2026 Form 4: McClain Sean, Director

Gave up 23,293 shares to cover exercise price or tax ($237K)

14 Oct 2026 Form 4: Bedrick Todd, SVP, CAO

Gave up 22,325 shares to cover exercise price or tax ($227K)

14 Oct 2026 Form 4: Jonasson Zachariah, CFO / CBO

Gave up 387 shares to cover exercise price or tax ($3.93K)

01 Sep 2026 Form 4: Jonasson Zachariah, CFO / CBO

Gave up 8,320 shares to cover exercise price or tax ($72.5K)

11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201

07 Aug 2026 Form 4: Somaratne Ransi Mudalinayake, CMO, Head of R&D

Granted 650,000 Stock Option (right to buy) · Granted 383,000 Stock Option (right to buy)

07 Aug 2026 Form 3: Somaratne Ransi Mudalinayake, CMO, Head of R&D

No securities owned

06 Jul 2026 Form 4: Szela Mary T, Director

Bought 12,900 shares ($149K)

26 Jun 2026 Form 4: McClain Sean, Director

Gave up 59,896 shares to cover exercise price or tax ($603K)

24 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Absci Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an ag...

24 Jun 2026 424B5
24 Jun 2026 8-K: Other Events

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

15 Jun 2026 Form 4/A: Szela Mary T, Director

Received 8,400 shares as a grant or award · Granted 33,200 Stock Option (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support